methylphenidate has been researched along with Daytime Sleepiness in 30 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Treatment with methylphenidate showed a significant change in median scores on the Daytime Sleepiness Scale (-3." | 9.16 | Efficacy and tolerability of a 20-mg dose of methylphenidate for the treatment of daytime sleepiness in adult patients with myotonic dystrophy type 1: a 2-center, randomized, double-blind, placebo-controlled, 3-week crossover trial. ( Bouchard, JP; Mathieu, J; Puymirat, J, 2012) |
| " His progressively worsening excessive daytime sleepiness (EDS) was treated with methylphenidate hydrochloride." | 7.71 | Methylphenidate hydrochloride for excessive daytime sleepiness in a patient with myotonic dystrophy. ( Aizawa, C; Hirata, K; Miyamoto, M; Miyamoto, T; Suga, T; Takekawa, H, 2002) |
| "Excessive daytime sleepiness due to any cause can result in various symptoms similar to those used for the diagnosis of attention deficit/hyperactivity disorder (ADHD)." | 5.35 | Sleep and daytime sleepiness in methylphenidate medicated and un-medicated children with attention-deficit/hyperactivity disorder (ADHD). ( Ashwal, J; Bentley, A; Cockcroft, K, 2009) |
| "The hypersomnolence was associated with marked elevations in the serum prolactin level." | 5.29 | Menstrual-associated sleep disorder: an unusual hypersomniac variant associated with both menstruation and amenorrhea with a possible link to prolactin and metoclopramide. ( Bamford, CR, 1993) |
| " Treatment with methylphenidate showed a significant change in median scores on the Daytime Sleepiness Scale (-3." | 5.16 | Efficacy and tolerability of a 20-mg dose of methylphenidate for the treatment of daytime sleepiness in adult patients with myotonic dystrophy type 1: a 2-center, randomized, double-blind, placebo-controlled, 3-week crossover trial. ( Bouchard, JP; Mathieu, J; Puymirat, J, 2012) |
| "On the basis of this review, we came to the conclusion that methylphenidate is used to ameliorate opioid-induced somnolence, to augment the analgesic effects of opioids, to treat depression, and to improve cognitive function in patients with cancer." | 4.81 | Palliative uses of methylphenidate in patients with cancer: a review. ( Dreisbach, A; Kahn, MJ; Lertora, JJ; Rozans, M, 2002) |
| " His progressively worsening excessive daytime sleepiness (EDS) was treated with methylphenidate hydrochloride." | 3.71 | Methylphenidate hydrochloride for excessive daytime sleepiness in a patient with myotonic dystrophy. ( Aizawa, C; Hirata, K; Miyamoto, M; Miyamoto, T; Suga, T; Takekawa, H, 2002) |
| "MLN8054 dosing for up to 14 days of a 28-day cycle was feasible." | 2.76 | Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. ( Burris, H; Cohen, RB; Danaee, H; Dees, EC; Ecsedy, J; Eton, O; Fingert, H; Galvin, K; Infante, JR; Jones, S; Lee, Y; Liu, H; Manfredi, M; O'Neil, BH; Stringer, B; von Mehren, M, 2011) |
| "Additional testing in patients with hypersomnia should include a polysomnography in order to exclude other sleeping disorders, and a mean sleep latency test." | 2.50 | [Hypersomnia: a diagnostic problem]. ( Kranenburg, G; Teunissen, LL, 2014) |
| "Only daytime sleepiness was more common for those receiving α2-adrenergic agonists vs stimulants (38% vs 3%); several adverse effects were reported more commonly for those receiving stimulants vs α2-adrenergic agonists, including moodiness/irritability (50% vs 29%), appetite suppression (38% vs 7%), and difficulty sleeping (21% vs 11%)." | 1.62 | α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder. ( Barbaresi, W; Bax, A; Blum, NJ; Cacia, J; Deavenport-Saman, A; Friedman, S; Harstad, E; LaRosa, A; Loe, IM; Mittal, S; Shults, J; Tulio, S; Vanderbilt, D, 2021) |
| "Childhood narcolepsy is associated with various emotional, behavioural and cognitive dysfunctions as well as with psychiatric and neurodevelopmental disorders: anxiety, depression, attention deficit hyperactivity disorder and psychosis." | 1.48 | Childhood narcolepsy and autism spectrum disorders: four case reports. ( Dudova, I; Hrdlicka, M; Mohaplova, M; Nevsimalova, S; Prihodova, I, 2018) |
| "She was diagnosed with obstructive sleep apnea (OSA) and underwent tonsillectomy and adenoidectomy." | 1.39 | Narcolepsy with obstructive sleep apnea in a 4-year-old Korean girl: a case report. ( Cho, M; Hwang, S; Jang, K; Kwon, S; Seo, H, 2013) |
| "Excessive daytime sleepiness due to any cause can result in various symptoms similar to those used for the diagnosis of attention deficit/hyperactivity disorder (ADHD)." | 1.35 | Sleep and daytime sleepiness in methylphenidate medicated and un-medicated children with attention-deficit/hyperactivity disorder (ADHD). ( Ashwal, J; Bentley, A; Cockcroft, K, 2009) |
| " Members of the high-dose group (n = 58) had received at least 1 stimulant at a dosage > or = 120% of the maximum recommended by the American Academy of Sleep Medicine Standards of Practice Committee." | 1.33 | Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: a case-control study. ( Auger, RR; Goodman, SH; Krahn, LE; Pankratz, VS; Silber, MH; Slocumb, NL, 2005) |
| "Excessive daytime sleepiness and abnormal sleep-wake patterns are becoming increasingly pervasive in modern society." | 1.32 | Pharmacologic management of daytime sleepiness. ( Schwartz, JR, 2004) |
| "We encountered two cases expressing excessive daytime sleepiness (EDS) and manifesting two or more sleep-onset rapid eye movement (REM) periods in the multiple sleep latency test." | 1.30 | Two cases of HLA-DR2-negative hypersomnia manifesting sleep-onset rapid eye movement periods in the multiple sleep latency test. ( Emura, N; Kuroda, K; Mandai, M; Matsumura, H; Satani, S; Ueda, S; Yoneda, H; Yoshida, Y, 1999) |
| " The elimination half-life of (+)-methylphenidate in patients was within the range of 2." | 1.29 | Pharmacokinetics and pharmacodynamics of (+)-threo-methylphenidate enantiomer in patients with hypersomnia. ( Aoyama, T; Honda, Y; Iga, T; Kotaki, H; Sasaki, T; Sawada, Y; Sudoh, Y, 1994) |
| "The hypersomnolence was associated with marked elevations in the serum prolactin level." | 1.29 | Menstrual-associated sleep disorder: an unusual hypersomniac variant associated with both menstruation and amenorrhea with a possible link to prolactin and metoclopramide. ( Bamford, CR, 1993) |
| "The cause of this syndrome is unknown, in some cases a relationship between infectious disease or traumatic brain damage has been postulated." | 1.28 | [The Kleine-Levin syndrome]. ( Boer, F; Njiokiktjien, C; Smit, LM; Smith, F; Visscher, F, 1989) |
| "However, his hypersomnolence could be attributed to a central dysfunction, and during a follow-up period of 3 years, was successfully treated with methylphenidate." | 1.27 | Treatment of hypersomnolence in myotonic dystrophy with a CNS stimulant. ( Boogaard, JM; van den Berg, B; van der Meché, FG, 1986) |
| "A possibly different mechanism in hypersomnia and hypersexuality is speculated." | 1.26 | The Kleine-Levine syndrome--a variant? ( Nair, NP; Yassa, R, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (20.00) | 18.7374 |
| 1990's | 4 (13.33) | 18.2507 |
| 2000's | 11 (36.67) | 29.6817 |
| 2010's | 8 (26.67) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Harstad, E | 1 |
| Shults, J | 1 |
| Barbaresi, W | 1 |
| Bax, A | 1 |
| Cacia, J | 1 |
| Deavenport-Saman, A | 1 |
| Friedman, S | 1 |
| LaRosa, A | 1 |
| Loe, IM | 1 |
| Mittal, S | 1 |
| Tulio, S | 1 |
| Vanderbilt, D | 1 |
| Blum, NJ | 1 |
| Prihodova, I | 1 |
| Dudova, I | 1 |
| Mohaplova, M | 1 |
| Hrdlicka, M | 1 |
| Nevsimalova, S | 1 |
| Aguilar, AC | 1 |
| Brant, PHRC | 1 |
| Tufik, S | 1 |
| Coelho, FM | 1 |
| Kwon, S | 1 |
| Jang, K | 1 |
| Hwang, S | 1 |
| Cho, M | 1 |
| Seo, H | 1 |
| Kranenburg, G | 1 |
| Teunissen, LL | 1 |
| Gahr, M | 1 |
| Kölle, MA | 1 |
| Findling, RL | 1 |
| Cockcroft, K | 1 |
| Ashwal, J | 1 |
| Bentley, A | 1 |
| Dees, EC | 1 |
| Infante, JR | 1 |
| Cohen, RB | 1 |
| O'Neil, BH | 1 |
| Jones, S | 1 |
| von Mehren, M | 1 |
| Danaee, H | 1 |
| Lee, Y | 1 |
| Ecsedy, J | 1 |
| Manfredi, M | 1 |
| Galvin, K | 1 |
| Stringer, B | 1 |
| Liu, H | 1 |
| Eton, O | 1 |
| Fingert, H | 1 |
| Burris, H | 1 |
| Dempsey, M | 1 |
| Puymirat, J | 1 |
| Bouchard, JP | 1 |
| Mathieu, J | 1 |
| Westberg, J | 1 |
| Gobel, BH | 1 |
| Golan, N | 1 |
| Shahar, E | 1 |
| Ravid, S | 1 |
| Pillar, G | 1 |
| Schwartz, JR | 1 |
| Sangal, RB | 1 |
| Owens, JA | 1 |
| Sangal, J | 1 |
| Auger, RR | 1 |
| Goodman, SH | 1 |
| Silber, MH | 1 |
| Krahn, LE | 1 |
| Pankratz, VS | 1 |
| Slocumb, NL | 1 |
| Alisky, JM | 1 |
| Gruber, R | 1 |
| Grizenko, N | 1 |
| Schwartz, G | 1 |
| Bellingham, J | 1 |
| Guzman, R | 1 |
| Joober, R | 1 |
| Lenz, H | 1 |
| Aoyama, T | 1 |
| Sasaki, T | 1 |
| Kotaki, H | 1 |
| Sawada, Y | 1 |
| Sudoh, Y | 1 |
| Honda, Y | 1 |
| Iga, T | 1 |
| Bamford, CR | 1 |
| Miller, SC | 1 |
| Yoshida, Y | 1 |
| Kuroda, K | 1 |
| Mandai, M | 1 |
| Satani, S | 1 |
| Emura, N | 1 |
| Ueda, S | 1 |
| Matsumura, H | 1 |
| Yoneda, H | 1 |
| Rozans, M | 1 |
| Dreisbach, A | 1 |
| Lertora, JJ | 1 |
| Kahn, MJ | 1 |
| Miyamoto, T | 1 |
| Miyamoto, M | 1 |
| Suga, T | 1 |
| Aizawa, C | 1 |
| Takekawa, H | 1 |
| Hirata, K | 1 |
| Billiard, M | 1 |
| Guilleminault, C | 1 |
| Dement, WC | 1 |
| Chiles, JA | 1 |
| Wilkus, RJ | 1 |
| Yassa, R | 1 |
| Nair, NP | 1 |
| Visscher, F | 1 |
| Smit, LM | 1 |
| Smith, F | 1 |
| Boer, F | 1 |
| Njiokiktjien, C | 1 |
| van der Meché, FG | 1 |
| Boogaard, JM | 1 |
| van den Berg, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Pharmacologic Management of ADHD in Children and Youth With Autism Spectrum Disorder[NCT05916339] | Phase 4 | 500 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | ||
| A Phase I/II Study of Alisertib in Combination With Abiraterone and Prednisone for Patients With Castration-Resistant Prostate Cancer After Progression on Abiraterone[NCT01848067] | Phase 1/Phase 2 | 9 participants (Actual) | Interventional | 2013-08-14 | Completed | ||
| Phase 2/3 Study of Efficacy and Tolerability of Methylphenidate in the Treatment of Excessive Daytime Sleepiness in Myotonic Dystrophy Type 1[NCT01421992] | Phase 2/Phase 3 | 28 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Randomized Study Evaluating the Antiasthenic Effect of Methylphenidate (Ritalin) in Palliative Care in Cancer Patients[NCT00273741] | Phase 3 | 39 participants (Actual) | Interventional | 2007-01-31 | Terminated (stopped due to difficulty of recrutement) | ||
| A Parallel-group, Double-blind, Placebo-controlled Study of Methylphenidate as an Add on Therapy for Mirtazapine in the Treatment of Major Depressive Disorder in Cancer Patients Under Palliative Care[NCT01497548] | Phase 3 | 120 participants (Anticipated) | Interventional | 2011-03-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Compared between the two patient subsets using the nonparametric Mann-Whitney test. A comparison of CTC counts between baseline and at progression for those who have progressed will be carried out using either a paired t test or the nonparameteric Wilcoxon matched pairs test. (NCT01848067)
Timeframe: Baseline up to 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Alisertib, Abiraterone Acetate, Prednisone) | 3 |
Summarized with descriptive statistics. (NCT01848067)
Timeframe: Up to 21 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Alisertib, Abiraterone Acetate, Prednisone) | 2 |
3 reviews available for methylphenidate and Daytime Sleepiness
| Article | Year |
|---|---|
[Hypersomnia: a diagnostic problem].
Topics: Adolescent; Cataplexy; Central Nervous System Stimulants; Diagnosis, Differential; Disorders of Exce | 2014 |
Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; | 2008 |
Palliative uses of methylphenidate in patients with cancer: a review.
Topics: Analgesics, Opioid; Central Nervous System Stimulants; Cognition Disorders; Depression; Disorders of | 2002 |
Palliative uses of methylphenidate in patients with cancer: a review.
Topics: Analgesics, Opioid; Central Nervous System Stimulants; Cognition Disorders; Depression; Disorders of | 2002 |
Palliative uses of methylphenidate in patients with cancer: a review.
Topics: Analgesics, Opioid; Central Nervous System Stimulants; Cognition Disorders; Depression; Disorders of | 2002 |
Palliative uses of methylphenidate in patients with cancer: a review.
Topics: Analgesics, Opioid; Central Nervous System Stimulants; Cognition Disorders; Depression; Disorders of | 2002 |
3 trials available for methylphenidate and Daytime Sleepiness
| Article | Year |
|---|---|
Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aurora Kinases; Benzaze | 2011 |
Efficacy and tolerability of a 20-mg dose of methylphenidate for the treatment of daytime sleepiness in adult patients with myotonic dystrophy type 1: a 2-center, randomized, double-blind, placebo-controlled, 3-week crossover trial.
Topics: Adult; Aged; Central Nervous System Stimulants; Cross-Over Studies; Disorders of Excessive Somnolenc | 2012 |
Performance on the continuous performance test in children with ADHD is associated with sleep efficiency.
Topics: Arousal; Attention; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder | 2007 |
24 other studies available for methylphenidate and Daytime Sleepiness
| Article | Year |
|---|---|
α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder.
Topics: Adrenergic alpha-2 Receptor Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervous | 2021 |
Childhood narcolepsy and autism spectrum disorders: four case reports.
Topics: Age of Onset; Antidepressive Agents; Anxiety Disorders; Asperger Syndrome; Attention Deficit Disorde | 2018 |
Finding a needle in the haystack-narcolepsy and obstructive sleep apnea.
Topics: Adult; Cephalometry; Diagnosis, Differential; Disorders of Excessive Somnolence; Humans; Male; Methy | 2019 |
Narcolepsy with obstructive sleep apnea in a 4-year-old Korean girl: a case report.
Topics: Adenoidectomy; Asian People; Child, Preschool; Disorders of Excessive Somnolence; Female; Humans; Me | 2013 |
Methylphenidate intoxication: somnolence as an uncommon clinical symptom and proof of overdosing by increased serum levels of ritalinic acid.
Topics: Adult; Central Nervous System Stimulants; Disorders of Excessive Somnolence; Humans; Male; Methylphe | 2014 |
Sleep and daytime sleepiness in methylphenidate medicated and un-medicated children with attention-deficit/hyperactivity disorder (ADHD).
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2009 |
A true mystery diagnosis.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Central Nervous System Stimulants; Confusion; Diagnosis, | 2011 |
Methylphenidate use for the management of opioid-induced sedation.
Topics: Analgesics, Opioid; Central Nervous System Stimulants; Disorders of Excessive Somnolence; Drug Thera | 2004 |
Sleep disorders and daytime sleepiness in children with attention-deficit/hyperactive disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Disorders o | 2004 |
Pharmacologic management of daytime sleepiness.
Topics: Amphetamines; Benzhydryl Compounds; Central Nervous System Stimulants; Disorders of Excessive Somnol | 2004 |
Patients with attention-deficit/hyperactivity disorder without observed apneic episodes in sleep or daytime sleepiness have normal sleep on polysomnography.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervou | 2005 |
Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: a case-control study.
Topics: Adult; Anorexia; Case-Control Studies; Central Nervous System Stimulants; Disorders of Excessive Som | 2005 |
A new approach to Parkinson's disease combining caffeine, methylphenidate, and anticholinergic agents: case histories, pharmacological data, and a conceptual framework from traditional Chinese medicine.
Topics: Adult; Aged; Antiparkinson Agents; Caffeine; Disorders of Excessive Somnolence; Drug Therapy, Combin | 2006 |
[Kleine-Levin-syndrome (author's transl)].
Topics: Adolescent; Body Water; Disorders of Excessive Somnolence; Feeding and Eating Disorders; Female; Hum | 1980 |
Pharmacokinetics and pharmacodynamics of (+)-threo-methylphenidate enantiomer in patients with hypersomnia.
Topics: Administration, Oral; Adolescent; Adult; Disorders of Excessive Somnolence; Female; Humans; Male; Me | 1994 |
Menstrual-associated sleep disorder: an unusual hypersomniac variant associated with both menstruation and amenorrhea with a possible link to prolactin and metoclopramide.
Topics: Adult; Amenorrhea; Arthritis, Rheumatoid; Disorders of Excessive Somnolence; Estrogen Replacement Th | 1993 |
Methylphenidate for clozapine sedation.
Topics: Clozapine; Disorders of Excessive Somnolence; Drug Monitoring; Humans; Male; Methylphenidate; Middle | 1996 |
Two cases of HLA-DR2-negative hypersomnia manifesting sleep-onset rapid eye movement periods in the multiple sleep latency test.
Topics: Adult; Central Nervous System Stimulants; Circadian Rhythm; Diagnosis, Differential; Disorders of Ex | 1999 |
Methylphenidate hydrochloride for excessive daytime sleepiness in a patient with myotonic dystrophy.
Topics: Adult; Central Nervous System Stimulants; Disorders of Excessive Somnolence; Evoked Potentials, Audi | 2002 |
A menstruation-linked periodic hypersomnia. Kleine-Levin syndrome or new clinical entity?
Topics: Adolescent; Disorders of Excessive Somnolence; Electroencephalography; Estrogens, Conjugated (USP); | 1975 |
Behavioral manifestations of the Kleine-Levin syndrome.
Topics: Adolescent; Behavior; Disorders of Excessive Somnolence; Electroencephalography; Humans; Male; Menta | 1976 |
The Kleine-Levine syndrome--a variant?
Topics: Adult; Disorders of Excessive Somnolence; Feeding and Eating Disorders; Humans; Hypothalamus; Male; | 1978 |
[The Kleine-Levin syndrome].
Topics: Adolescent; Child; Disorders of Excessive Somnolence; Humans; Hyperphagia; Male; Methylphenidate; Sl | 1989 |
Treatment of hypersomnolence in myotonic dystrophy with a CNS stimulant.
Topics: Adult; Disorders of Excessive Somnolence; Humans; Male; Methylphenidate; Myotonic Dystrophy; Respira | 1986 |